about
Old DAT and new data: positive direct antiglobulin test identifies a subgroup with poor outcome among chronic lymphocytic leukemia stage A patients.miR-125b and miR-532-3p predict the efficiency of rituximab-mediated lymphodepletion in chronic lymphocytic leukemia patients. A French Innovative Leukemia Organization study.Induction of endoplasmic reticulum calcium pump expression during early leukemic B cell differentiation.A complementary role of multiparameter flow cytometry and high-throughput sequencing for minimal residual disease detection in chronic lymphocytic leukemia: an European Research Initiative on CLL study.Routine diagnostic procedures of myelodysplastic syndromes: value of a structural blood cell parameter (NEUT-X) determined by the Sysmex XE-2100™.Evaluation of paroxysmal nocturnal hemoglobinuria screening by flow cytometry through multicentric interlaboratory comparison in four countries.Evaluating abbreviated induction with fludarabine, cyclophosphamide, and dose-dense rituximab in elderly patients with chronic lymphocytic leukemia.Response to rituximab in B-CLL patients is adversely impacted by frequency of IL-10 competent B cells and FcγRIIIa polymorphism. A study of FCGCLL/WM and GOELAMS groups.Prognosis of Binet stage A chronic lymphocytic leukemia patients: the strength of routine parameters.Flow cytometry APC-tandem dyes are degraded through a cell-dependent mechanism.Different expression of CD41 on human lymphoid and myeloid progenitors from adults and neonates.Rituximab for patients with refractory mucous membrane pemphigoid.Down-regulation of CXCR4 and CD62L in chronic lymphocytic leukemia cells is triggered by B-cell receptor ligation and associated with progressive disease.Improving efficiency and sensitivity: European Research Initiative in CLL (ERIC) update on the international harmonised approach for flow cytometric residual disease monitoring in CLL.Excess mortality after treatment with fludarabine and cyclophosphamide in combination with alemtuzumab in previously untreated patients with chronic lymphocytic leukemia in a randomized phase 3 trial.[Expression of proliferation marker Ki 67 in chronic lymphocytic leukemia]Synchronous FIP1L1-PDGFRA-positive chronic eosinophilic leukemia and T-cell lymphoblastic lymphoma: a bilineal clonal malignancy.Prognostic impact of p27KIP1 expression in cyclin D1 positive lymphoproliferative disorders.HBME-1 is expressed by erythroid precursors in early maturation stage and can be a valuable tool for evaluation of dyserythropoiesis in bone marrow core biopsy specimens.TP53 mutations are early events in chronic lymphocytic leukemia disease progression and precede evolution to complex karyotypes.Evaluation of an algorithm based on peripheral blood hematopoietic progenitor cell and CD34+ cell concentrations to optimize peripheral blood progenitor cell collection by apheresis.[Bone marrow aspiration for diagnostic purposes]Deciphering leukemic B-cell chronic lymphoproliferative disorders.Survival response to B-cell receptor ligation is restricted to progressive chronic lymphocytic leukemia cells irrespective of Zap70 expression.The degree of BCR and NFAT activation predicts clinical outcomes in chronic lymphocytic leukemia.Evaluation of ZAP-70 expression by flow cytometry in chronic lymphocytic leukemia: A multicentric international harmonization processNational standardization of ZAP-70 determination by flow cytometry: The French experienceIntracellular trafficking of the alphaIIbbeta3 receptor antagonist, abciximab, in normal and Glanzmann's disease megakaryocytesThromboxane synthase has the same pattern of expression as platelet specific glycoproteins during human megakaryocyte differentiationUse of hematopoietic progenitor cell count on the Sysmex XE-2100 for peripheral blood stem cell harvest monitoring[Cold agglutinin!...].Evaluation of Fluorescently Labeled Aerolysin as a New Kind of Reagent for Flow Cytometry Tests: Optimization of Use of FLAER, Hints, and Limits
P50
Q30855660-1DAE597E-F411-40B1-953E-9DE28C7D7DF0Q33574184-1CBC0499-7C83-490F-A26B-1FBBDC2C72FAQ33837603-7BCD9B40-2657-4B74-B8F9-47A44F69FDACQ36799192-206EC92A-57B5-4D3A-8E30-812B160A5252Q37776545-799A6DA1-31A0-4C5A-A635-06FAE1DB382BQ40317338-E994A4AF-933F-4438-99ED-E51B64ADFF4EQ41125227-B0403572-7FA8-4B33-97F9-3DF4BEAAB28AQ42553292-FAA53555-C2DB-40EC-9DFC-EF548BA6EE0AQ42925708-F6D9CF9F-C518-4D05-BF03-DBD4AD6587BEQ43279356-8E0F8B72-97AC-4C5B-AB7F-7F9313FD34C6Q43551010-265303CC-92E8-4263-BE43-382D5889F00CQ43705034-F2C3FA70-2B49-48FD-A027-19492FD38AF0Q44214843-2BCC6CBB-CCE9-4761-891C-9B578109115BQ44539030-80A5A554-ACF3-474A-9A45-20B80303F447Q44579242-F452C53F-DABB-4C31-B9E4-0177B1728A4CQ46810264-245D9E45-E3A3-43B1-AE63-212CF291CF11Q46889637-158921CF-90E0-4A4D-8FEA-4E6DB21E6E75Q47929697-FC78C926-4B5D-4ADF-8347-A0C656CF4768Q51598955-154B6189-26B0-4500-8AF3-B3C7636851E5Q51716282-AE3AB4CF-D63C-4B10-BD8C-BD70AC2A1FCFQ51905616-CFB916DD-96C8-4CD2-9A79-ADD21CBCDF83Q52095285-503D92DD-6F8D-44C6-9151-584CE1289EA0Q53591043-B61F4389-9C60-45D1-B828-C69D024A26A9Q53610680-4290AF51-0518-49D0-98E5-1C48C89379B7Q54509665-ADE13653-FEB4-4E27-9F9A-58840121B888Q56461748-5CE86FC9-A8E7-4C40-99AD-3FE36E5ED8D1Q58041738-5DD50241-405F-4953-B247-0F5266727BD1Q73293602-0E1D5E4F-D558-4AD2-B585-006031640E14Q73818095-4ACA0EF7-95AF-48C4-985A-FD151B66BFE4Q79844243-CAFACEBE-7508-4245-AA6E-DA543FD4EB62Q81132123-E417C1C2-8040-4D8B-9C80-F34BBB32DFDEQ89318098-06457CDF-2AF7-4775-ABFE-9BC8D0E0B876
P50
description
hulumtues
@sq
researcher
@en
wetenschapper
@nl
հետազոտող
@hy
name
Rémi Letestu
@ast
Rémi Letestu
@en
Rémi Letestu
@es
Rémi Letestu
@nl
Rémi Letestu
@sl
type
label
Rémi Letestu
@ast
Rémi Letestu
@en
Rémi Letestu
@es
Rémi Letestu
@nl
Rémi Letestu
@sl
prefLabel
Rémi Letestu
@ast
Rémi Letestu
@en
Rémi Letestu
@es
Rémi Letestu
@nl
Rémi Letestu
@sl
P106
P21
P31
P496
0000-0002-2437-2656
P569
2000-01-01T00:00:00Z